ScholarIQanswers from OpenAlex & ORCID
Chong‐Rui Xu
ResearcherPublications, citations & collaboration network
Chong‐Rui Xu is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Chong‐Rui Xu have?
ScholarIQindexed works
Chong‐Rui Xu has 280 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Chong‐Rui Xu have?
ScholarIQcitation count
Chong‐Rui Xu has 7,553 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Chong‐Rui Xu?
ScholarIQh-index
Chong‐Rui Xu has an h-index of 37 in OpenAlex.
What is the i10-index of Chong‐Rui Xu?
ScholarIQi10-index
Chong‐Rui Xu has an i10-index of 72 in OpenAlex.
What is the ORCID of Chong‐Rui Xu?
ScholarIQorcid
The ORCID for Chong‐Rui Xu is on the source record.
What is the OpenAlex record for Chong‐Rui Xu?
ScholarIQopenalex
The OpenAlex for Chong‐Rui Xu is on the source record.
What are the most-cited papers on Chong‐Rui Xu?
ScholarIQmost cited works
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi‐Long Wu, Caicun Zhou, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wěi Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Chong‐Rui Xu, Dan Massey, Miyoung Kim, Yang Shi, Sarayut Lucien Geater
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
Zhong‐Yi Dong, Jia‐Tao Zhang, Si‐Yang Maggie Liu, Jian Su, Chao Zhang, Zhi Xie, Qing Zhou, Hai‐Yan Tu, Chong‐Rui Xu, Li‐Xu Yan, Yufa Li, Wen‐Zhao Zhong, Yi‐Long Wu
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
Y.S. Li, Bo Jiang, Jin‐Ji Yang, X.C. Zhang, Zhou Zhang, J.Y. Ye, Wen‐Zhao Zhong, Hai‐Yan Tu, H.J. Chen, Z. Wang, Chong‐Rui Xu, B.C. Wang, Hao Du, Shaokun Chuai, Han Han‐Zhang, Jian Su, Qing Zhou, Xue‐Ning Yang, Wanting Guo, Hong‐Hong Yan, Y.H. Liu, Li‐Xu Yan, Biao Huang, Mei-Mei Zheng, Yi‐Long Wu
HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers
Bob T. Li, Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai, Sophie Shifman, Hai‐Yan Tu, Mackenzie L. Myers, Chong‐Rui Xu, Marissa S. Mattar, Inna Khodos, Megan Little, Besnik Qeriqi, Gregory Weitsman, Clare J. Wilhem, Alshad S. Lalani, Irmina Diala, Rachel A. Freedman, Nancy U. Lin, David B. Solit, Michael F. Berger, Paul R. Barber, Tony Ng, Michael Offin, James M. Isbell, David R. Jones, Helena A. Yu, Sheeno Thyparambil, Wei‐Li Liao, Anuja Bhalkikar, Fabiola Cecchi, David M. Hyman, Jason S. Lewis, Darren J. Buonocore, Alan L. Ho, Vicky Makker, Jorge S. Reis‐Filho, Pedram Razavi, Maria E. Arcila, Mark G. Kris, John T. Poirier, Ronglai Shen, Junji Tsurutani, Gary A. Ulaner, Elisa de Stanchina, Neal Rosen, Charles M. Rudin, Maurizio Scaltriti
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
Hao Sun, Si‐Yang Maggie Liu, Jiaying Zhou, Jintian Xu, Huang-Kai Zhang, Hong‐Hong Yan, Jiaojiao Huan, Pingping Dai, Chong‐Rui Xu, Jian Su, Yanfang Guan, Xin Yi, Rongshan Yu, Wen‐Zhao Zhong, Yi‐Long Wu